Comparative Pharmacology
Head-to-head clinical analysis: NATESTO versus TLANDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATESTO versus TLANDO.
NATESTO vs TLANDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; testosterone binds to androgen receptors, activating gene transcription for male sexual development and maintenance of secondary sexual characteristics.
TLANDO (testosterone undecanoate) is an androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle mass, bone density, and secondary sexual characteristics. Testosterone is converted to dihydrotestosterone (DHT) via 5α-reductase in target tissues, exerting both androgenic and anabolic effects.
One 10 mg buccal tablet applied twice daily to the gum region above the incisor tooth, approximately 12 hours apart; morning and evening.
TLANDO (testosterone undecanoate) is administered orally. The recommended adult dose is 225 mg twice daily (approximately every 12 hours) with a meal containing fat. Swallow capsules whole; do not chew or crush.
None Documented
None Documented
The terminal elimination half-life of testosterone after intramuscular injection of testosterone enanthate is approximately 8 days (range 4–12 days), reflecting slow absorption from the oily depot. This prolonged half-life supports a dosing interval of every 2–4 weeks.
The terminal elimination half-life of testosterone is 10-100 minutes; however, for TLANDO (testosterone undecanoate) after oral administration, the apparent half-life is approximately 7-10 hours due to the slow release from chylomicrons and prolonged absorption.
Following intramuscular administration of testosterone enanthate, approximately 90% of the dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (e.g., androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone in urine is negligible (<1%).
Approximately 90% of a dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites; about 6% is excreted in feces via bile. Unchanged testosterone accounts for less than 1% of urinary excretion.
Category C
Category C
Androgen
Androgen/hormone replacement